Answers are grounded in this paper and cite their sources.
Arterial embolization has emerged as a minimally invasive option for refractory plantar fasciitis, but its efficacy and safety remain uncertain. We systematically searched MEDLINE, Embase, Scopus, CINAHL, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform through June 26, 2026, and appraised eligible human studies with the Joanna Briggs Institute case-series checklist. Seven uncontrolled studies included 165 unique patients and 174 reported patient-, foot-, or procedure-level analysis units. Five studies contributed to the approximately 6-month pain synthesis; the pooled observed within-group pain reduction was 5.87 points on a 0–10 scale (95% confidence interval [CI], 4.46–7.28; I 2 = 96.0%; 95% prediction interval, 2.53–9.20). Technical success was 97.0% (95% CI, 93.7–98.6%). An exploratory responder synthesis combined non-equivalent study definitions and should not be interpreted as a common clinical response rate. No major procedure-related adverse event was reported, but rare and long-term harms cannot be excluded. The evidence is uncontrolled, heterogeneous, and of very low certainty; therefore, the pooled estimates describe observed pre-post changes rather than causal treatment effects. Comparative trials with standardized techniques, outcomes, and long-term safety surveillance are required before routine use.
No takes yet. Share an insight, caveat, or question.
Rathor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: